Topic
The latest Pharma news and analysis from Tech Arcade.
BridgeBio's encaleret hit its Phase 3 target in 76% of ADH1 patients vs 4% on standard care, restored PTH in 91%, with an FDA decision set for May 8, 2027.
Eli Lilly is paying up to $2.88 billion for Merida Biosciences, a 16-month-old startup whose lead autoimmune drug is still in Phase 1.
Revolution Medicines' RASONQUE is the first broad RAS-targeted pill for metastatic pancreatic cancer, nearly doubling median survival to 13.2 months. The catch: $39,800 a month.
The FDA cleared Revolution Medicines' daraxonrasib, the first broad RAS-targeted pill for metastatic pancreatic cancer, doubling median survival to 13.2 months at a $477,000-a-year list price.
The FDA cleared GENGLYCOS, Ultragenyx's first gene therapy: a one-time $2.7 million infusion targeting the root cause of glycogen storage disease type Ia.
AusperBio raised $120M to push AHB-137, an antisense drug that cleared hepatitis B in 68% of a small trial, toward the first functional cure for a disease 240 million people live with.
Moderna and Merck's personalized mRNA cancer vaccine cleared Phase 3 in 1,137 melanoma patients — and Moderna's stock more than doubled before the full numbers were even released.
Takeda's Orzeyful is the first-in-class orexin agonist cleared to treat narcolepsy type 1 at its root cause — and Jefferies pegs peak sales near $2 billion.
Bristol Myers Squibb's Zenbexus is the first CELMoD approved for multiple myeloma — cleared on a doubled deep-remission rate (41% vs 21%) and priced at $29,500 a cycle.
Jazz Pharmaceuticals is paying $820M upfront — up to $1.32B — for Actio Biosciences and its Phase 1 KCNT1 epilepsy drug, aimed at just ~2,500 U.S. patients.
The FDA just approved mFlusiva, the first mRNA flu vaccine ever — 26.6% more effective than the standard shot in adults 50+, six months after the agency refused to review it.
Pathos AI committed up to $2.2 billion to license cancer drugs from Alphamab and AstraZeneca without inventing a single molecule. Inside the bet that AI's real job is picking patients, not chemistry.
Lilly and its manufacturing partner Resilience are putting $750 million into an Ohio campus to make more of the injector pens behind the diabetes and obesity boom -- 400 new jobs, full operations by early 2027.
Celcuity's first FDA drug, REVTORPYK, cut breast-cancer progression risk 76% and stretched median control from 2.0 to 9.3 months — yet the stock slid on a delayed launch and rough side effects.
Eli Lilly's triple-agonist shot retatrutide hit 22.6% weight loss in two more Phase 3 trials — its fifth straight win, with an FDA filing due Q1 2027.
Merck's Lipfendra (enlicitide) is the first oral PCSK9 inhibitor — a once-daily pill that cuts LDL up to 59%, matching the injectables at $315 a month.
